Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

Overview

Journal Vaccines (Basel)

Date 2021 Apr 30

PMID 33918085

Citations 58

Authors

Michael Jahn

Johannes Korth

Oliver Dorsch

Olympia Evdoxia Anastasiou

Burkhard Sorge-Hadicke

Bartosz Tyczynski

Anja Gackler

Oliver Witzke

Ulf Dittmer

Sebastian Dolff

Benjamin Wilde

Andreas Kribben

Affiliations

Soon will be listed here.

Abstract

mRNA-based SARS-CoV-2 vaccines offer a preventive strategy against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections that is of interest in the care of patients on hemodialysis (HDP). We measured humoral immune responses in 72 HDP after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech). Antibody responses were evaluated with an anti-SARS-CoV-2 IgG ChemiLuminescent ImmunoAssay (CLIA) two weeks after the second dose. In addition, SARS-CoV-2 IgG was determined in a control of 16 healthy healthcare workers (HCW). The control group of HCW has shown a strong antibody response with a median (MD (Q1; Q3)) antibody titer of 800.0 AU/mL (520.5; 800.0). In comparison to HCW, HDP under 60 years of age responded equally (597.0 AU/mL (410.5; 800.0), = 0.051). However, the antibody responses of the HDP negatively correlated with age (r = 0.2954 < 0.0001), leading to significantly lower antibody titers in HDP over 60 years (280.0 AU/mL (45.7; 477.0), < 0.0001). To thoroughly understand the immunogenicity of the new mRNA-based vaccines in HDP, longitudinal data on the effectiveness and durability of antibody responses are needed. Modifications of immunization schedules should be considered in HDP with low or without antibody responsiveness after standard vaccination to boost immune reactivity and prolong protective effects in these vulnerable patients.

Citing Articles

Network Analysis of Dysregulated Immune Response to COVID-19 mRNA Vaccination in Hemodialysis Patients.

Chang Y, Lee J, Huang K, Vagts C, Ascoli C, Edafetanure-Ibeh R Vaccines (Basel). 2024; 12(10).

PMID: 39460313 PMC: 11511558. DOI: 10.3390/vaccines12101146.

Immune Response after Anti-SARS-CoV-2 mRNA Vaccination in Relation to Cellular Immunity, Vitamin D and Comorbidities in Hemodialysis Patients.

Dalinkeviciene E, Gradauskiene B, Sakalauskaite S, Petruliene K, Vaiciuniene R, Skarupskiene I Microorganisms. 2024; 12(5).

PMID: 38792691 PMC: 11123711. DOI: 10.3390/microorganisms12050861.

Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine.

Chang Y, Huang K, Lee J, Vagts C, Ascoli C, Amin M Elife. 2024; 13.

PMID: 38656290 PMC: 11042800. DOI: 10.7554/eLife.83641.

The prevention and treatment of COVID-19 in patients treated with hemodialysis.

Zeng B, Zhou J, Peng D, Dong C, Qin Q Eur J Med Res. 2023; 28(1):410.

PMID: 37814329 PMC: 10563282. DOI: 10.1186/s40001-023-01389-9.

Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study.

Sripongpun P, Pinpathomrat N, Sophonmanee R, Ongarj J, Seepathomnarong P, Seeyankem B Vaccines (Basel). 2023; 11(9).

PMID: 37766131 PMC: 10534824. DOI: 10.3390/vaccines11091455.

References

Fabrizi F, Dixit V, Martin P, Jadoul M, Messa P . Meta-analysis: the impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease. Dig Dis Sci. 2011; 57(5):1366-72. DOI: 10.1007/s10620-011-1987-1. View

. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000; 355(9203):561-5. View

Hoxha E, Suling A, Turner J, Haubitz M, Floege J, Huber T . COVID-19 Prevalence and Mortality in Chronic Dialysis Patients. Dtsch Arztebl Int. 2021; 118(11):195-196. PMC: 8245864. DOI: 10.3238/arztebl.m2021.0160. View

Razzaghi H, Wang Y, Lu H, Marshall K, Dowling N, Paz-Bailey G . Estimated County-Level Prevalence of Selected Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19 Illness - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020; 69(29):945-950. PMC: 7377821. DOI: 10.15585/mmwr.mm6929a1. View

Patel N, Assimon M, Bruni E, McNutt L, Mason D . Incidence and Clinical Predictors of Nonresponse to Hepatitis B Vaccination among Patients Receiving Hemodialysis: Importance of Obesity. South Med J. 2015; 108(9):567-73. DOI: 10.14423/SMJ.0000000000000343. View

Ott U, Sauerbrei A, Lange J, Schafler A, Walther M, Wolf G . Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol. 2012; 201(3):297-302. DOI: 10.1007/s00430-012-0231-8. View

Mitra S, Stein G, Bhupalam S, Havlichek D . Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis. Clin Vaccine Immunol. 2016; 23(11):884-887. PMC: 5098022. DOI: 10.1128/CVI.00153-16. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Kong N, Beran J, Kee S, Miguel J, Sanchez C, Bayas J . A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2007; 73(7):856-62. DOI: 10.1038/sj.ki.5002725. View

10.

Weinberger B . Vaccines for the elderly: current use and future challenges. Immun Ageing. 2018; 15:3. PMC: 5778733. DOI: 10.1186/s12979-017-0107-2. View

11.

Vaziri N, Pahl M, Crum A, Norris K . Effect of uremia on structure and function of immune system. J Ren Nutr. 2011; 22(1):149-56. PMC: 3246616. DOI: 10.1053/j.jrn.2011.10.020. View

12.

Mastalerz-Migas A, Steciwko A, Brydak L . Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Adv Exp Med Biol. 2012; 756:285-90. DOI: 10.1007/978-94-007-4549-0_35. View

13.

Anderson E, Rouphael N, Widge A, Jackson L, Roberts P, Makhene M . Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; 383(25):2427-2438. PMC: 7556339. DOI: 10.1056/NEJMoa2028436. View

14.

Gandjour A, Armsen W, Wehmeyer W, Multmeier J, Tschulena U . Costs of patients with chronic kidney disease in Germany. PLoS One. 2020; 15(4):e0231375. PMC: 7182232. DOI: 10.1371/journal.pone.0231375. View

15.

. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2020; 36(1):87-94. PMC: 7771976. DOI: 10.1093/ndt/gfaa314. View

16.

Taji L, Thomas D, Oliver M, Ip J, Tang Y, Yeung A . COVID-19 in patients undergoing long-term dialysis in Ontario. CMAJ. 2021; 193(8):E278-E284. PMC: 8034346. DOI: 10.1503/cmaj.202601. View

17.

Asan A, Demirhan H, Sorkun H, Ozkan S, Aydin M, Akin D . Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol. 2017; 49(10):1845-1850. DOI: 10.1007/s11255-017-1616-9. View

18.

Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y . Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008; 3(5):1526-33. PMC: 4571158. DOI: 10.2215/CJN.00950208. View

19.

Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D . Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021; 384(20):1959-1961. PMC: 8008753. DOI: 10.1056/NEJMc2102051. View

20.

Fabrizi F, Dixit V, MARTIN P, Messa P . Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther. 2011; 33(7):815-21. DOI: 10.1111/j.1365-2036.2011.04589.x. View